Our science

Tumor
plasticity : a key driver of patient's relapse

Unlocking phenotypic plasticity

Cancer is a moving target causing:

Resistance mechanism
Immune escape
Relapsing process

Current treatment must be combined to be efficient

Lack of antigenicity

With limited and static targets

Lack of immunocenicity

With hidden targets to the immune system

Brenus Pharma:
the missing link ?

Brenus Pharma develops a next gen immun therapeutic based on adaptive & multispecific targets to educate the immune system to anticipate tumor plasticity & treatment resistance.

Engage with us ina change of paradigm

Efficient technology

Anticipates risks of tumor escape by targeting over 250 cancer-related antigens driven by relapse mechanism.

Answers huge unmet need in solid tumors : Platform strategy, combining impactful technologies, with standardized steps for a quicker generation of immunotherapy for solid tumors
Derisked approach

2nd generation of innovative cancer vaccine strategy : previous haptenized approaches show significative historical clinical DATA (Glioblastoma + Melanoma).

Preclinical package endoresed with FDA Pre-IND passed.

GMP manufacturing ready.

Top international scientific leader on board & experienced governance in Healthtech industries.
Limitless potential

IP by design-platform strategy ; 22 patent granted.

Tailored first-in-class drugs design.

Dynamic immuno-oncology market with mRNA and Personalized Cancer Vaccine.

Ensuring treatment's availability to a wide population of patient in therapeutic issue.